Compare Ascendis Pharma A/S (ASND) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs MINISO Group Holding Ltd — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while MINISO Group Holding Ltd trades at $11.47 (market cap $3.51B). The key difference: Ascendis Pharma A/S is far larger — about 5.1× MINISO Group Holding Ltd's market cap, and MINISO Group Holding Ltd pays a 5.65% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | MNSO | |
|---|---|---|
Market Cap | $17.74B | $3.51B |
Sector | Health | Technology |
52-Week High | $277.18 | $26.63 |
52-Week Low | $163.32 | $11.30 |
Enterprise Value | $18.11B | $4.17B |
Dividend Yield | — | 5.65% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
MNSO trades at $11.79, up 2.79% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported strong Q1 2026 earnings, beating expectations with EPS of $0.591, and announced a HK$2 billion share repurchase program on June 29, 2026. Revenue grew to $21.44 billion in 2025, with a net income margin of 8.98% and a P/E ratio of 12, indicating potential undervaluation.
The outlook is mixed: analyst consensus is 75% buy with growth potential from overseas expansion, but risks include margin compression and recent earnings misses. The stock's current price near the lower end of its 52-week range suggests caution amid bearish technical trends, though fundamentals support long-term value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
